25
Enterobacter sakazakii Enterobacter sakazakii General Microbiology General Microbiology Maria Nazarowec-White PhD Science Evaluation Unit Canadian Food Inspection Agency Contaminants and Natural Contaminants and Natural Toxicants Toxicants Subcommittee Meeting Subcommittee Meeting March 18, 2003 March 18, 2003

Enterobacter sakazakii General Microbiology Maria Nazarowec-White PhD Science Evaluation Unit Canadian Food Inspection Agency Maria Nazarowec-White PhD

  • View
    217

  • Download
    0

Embed Size (px)

Citation preview

Enterobacter Enterobacter sakazakii sakazakii General General

MicrobiologyMicrobiology

Maria Nazarowec-White PhD

Science Evaluation Unit

Canadian Food Inspection Agency

Maria Nazarowec-White PhD

Science Evaluation Unit

Canadian Food Inspection Agency

Contaminants and Natural ToxicantsContaminants and Natural ToxicantsSubcommittee MeetingSubcommittee Meeting

March 18, 2003March 18, 2003

OVERVIEWOVERVIEW

• HistoryHistory

• EcologyEcology

• Incidence on Canadian retail Incidence on Canadian retail marketmarket

• Growth characteristicsGrowth characteristics

• Phenotype characterizationPhenotype characterization

• GenotypingGenotyping

• PathogenicityPathogenicity

HistoryHistory

• Name Name Enterobacter sakazakiiEnterobacter sakazakii proposed in1980proposed in1980

• DNA hybridization studiesDNA hybridization studies

• Biochemical reactionsBiochemical reactions

• Yellow - pigmented coloniesYellow - pigmented colonies

Entrobacter sakazakiiEntrobacter sakazakii colonycolony

Electron micrograph of Electron micrograph of Entrobactor sakazakiiEntrobactor sakazakii

E. sakazakiiE. sakazakii and the and the environmentenvironment

Surface waterSurface water

MudMud

Rotting woodRotting wood

Bird dungBird dung

RodentsRodents

Domestic animalsDomestic animals

Cow’s milkCow’s milk

Clinical Strains of Clinical Strains of E. E. sakazakiisakazakii

• LondonLondon 22

• MontrealMontreal 11

• TorontoToronto 33

• LCDCLCDC 33

Dried-infant formula Dried-infant formula isolatesisolates

CompanyCompany Positive samples (%) Positive samples (%)

AA 3/24 (12)3/24 (12)

BB 2/24 (8)2/24 (8)

CC 0/24 (0)0/24 (0)

DD 1/24 (4)1/24 (4)

EE 2/24 (8)2/24 (8)

totaltotal 8/120 (6.7)8/120 (6.7)

Temperature Gradient Temperature Gradient IncubatorIncubator

• 10 strains10 strains

• Temperature range 4-50°CTemperature range 4-50°C

• 30 tubes in duplicate30 tubes in duplicate

TemperatureTemperatureGradient Gradient IncubatorIncubator

C = ClinicalC = ClinicalF = FoodF = Food

Strain Number

Minimum Growth

Temp °C

1C 72C 63C 64C 85C 5.56C 6.57F 7.58F 5.59F 6

10F 711F 5.5

Experimental Protocol Experimental Protocol Growth StudyGrowth Study

• 3 Different formulae3 Different formulae

• CocktailsCocktails– 5 clinical isolates5 clinical isolates

– 5 food isolates5 food isolates

• 4, 10 and 23°C4, 10 and 23°C

• Direct platingDirect plating

• Generation and lag timeGeneration and lag time

PhenotypingPhenotyping

• Biochemical Biochemical 3 biotypes3 biotypes

• Antibiograms Antibiograms 4 antibiograms4 antibiograms

Antibiotics used Antibiotics used

• AmpicillinAmpicillin

• CefotaximeCefotaxime

• ChloramphenicolChloramphenicol

• GentimicinGentimicin

• KanamycinKanamycin

• Polymixin BPolymixin B

• StreptomycinStreptomycin

• Trimethoprim-Trimethoprim-SulfamthoxazoleSulfamthoxazole

• TetracyclineTetracycline

• SulfisoxazoleSulfisoxazole

• CephalothinCephalothin

Antibiotic Resistance ProfileAntibiotic Resistance Profile

Antibiotic Antibiotic Number of strains (18)Number of strains (18)

• AmpicillinAmpicillin 11

• TetracyclineTetracycline 22

• ChloramphenicolChloramphenicol 33

• CephalothinCephalothin 1717

• SulfisoxazoleSulfisoxazole 1818

GenotypingGenotyping

• RibotypeRibotype

• Pulsed Field Gel Electrophoresis Pulsed Field Gel Electrophoresis (PFGE)(PFGE)

• Random Amplification of Random Amplification of Polymorphic DNA (RAPD)Polymorphic DNA (RAPD)

Source Strain RibotypeXba1 Spe1 Primer 1 Primer 2

Type strain 1 1 1 1 1LA 1 2 2 2 2LB 5 3 3 3 3MONT 6 4 4 4 4SK81 3 5 5 5 5SK90 3 6 6 6 6SK92 3 7 7 7 7LCDC1 7 8 8 8 8LCDC2 1 9 9 9 9LCDC3 1 10 10 10 10MNW1 8 11 11 11 11MNW2 4 12 12 12 12MNW3 2 13 13 13 13MNW4 2 14 13 13 14MNW5 2 15 14 14 15MNW6 10 16 15 15 16MNW7 9 17 16 16 17MNW8 2 18 17 17 18

PFGE RAPD

Food

Clin

ical

Genotypic profiles of E. sakazakii

Virulence FactorsVirulence Factors

• Suckling mouse assaySuckling mouse assay

• Three cell culture linesThree cell culture lines

• InfectivityInfectivity– intraperitonealintraperitoneal

– oral challengeoral challenge

Enterotoxin Screening Enterotoxin Screening

• 4 strains positive for enterotoxin 4 strains positive for enterotoxin productionproduction

• 3 clinical and 1 food3 clinical and 1 food

Morphological Responses Morphological Responses of Cell Lines to Filtratesof Cell Lines to Filtrates

• 1 clinical strain toxic to 3 cell lines1 clinical strain toxic to 3 cell lines

• more pronounced on Y-1 and Vero cellsmore pronounced on Y-1 and Vero cells

• no effect of boiling on Y-1 and CHO cellsno effect of boiling on Y-1 and CHO cells

• cytopathic effect decreased on Vero cellscytopathic effect decreased on Vero cells

• 2 clinical strains, no effect on 3 cell lines2 clinical strains, no effect on 3 cell lines

Infectivity studiesInfectivity studies

• i.p. injections lethal at 10i.p. injections lethal at 108 8 CFU per CFU per mousemouse

• within 3 days of dosingwithin 3 days of dosing

• per oral route 2 strains caused per oral route 2 strains caused deathdeath

• 1 clinical and 1 food1 clinical and 1 food

SummarySummary

• Incidence in dried infant-formula on the Incidence in dried infant-formula on the Canadian market found to be 6.7%Canadian market found to be 6.7%

• Minimum growth temperature 5.5-8.0°CMinimum growth temperature 5.5-8.0°C

• Generation time at room temperature 40 Generation time at room temperature 40 minmin

• Four of eighteen strains produce enterotoxinFour of eighteen strains produce enterotoxin

• Infectious doseInfectious dose

• Heterogeneity among strainsHeterogeneity among strains

What do we

do now??